Analysts Set Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Price Target at $10.14

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) have been given an average rating of “Hold” by the twenty-seven analysts that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.14.

TEVA has been the topic of a number of recent analyst reports. Credit Suisse Group reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, July 10th. SunTrust Banks cut their price objective on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating on the stock in a research report on Thursday, August 8th. Cowen set a $9.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Wednesday, August 7th. UBS Group set a $8.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, August 16th. Finally, Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Friday, July 5th.

Shares of TEVA stock traded up $0.23 during trading hours on Monday, reaching $8.16. The company’s stock had a trading volume of 26,114,552 shares, compared to its average volume of 21,282,044. The stock has a market capitalization of $8.66 billion, a P/E ratio of 2.91, a P/E/G ratio of 0.84 and a beta of 1.71. Teva Pharmaceutical Industries has a one year low of $6.07 and a one year high of $23.97. The firm’s fifty day simple moving average is $7.26 and its 200 day simple moving average is $9.40. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.02. The firm had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period last year, the company earned $0.78 EPS. As a group, equities research analysts forecast that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its stake in Teva Pharmaceutical Industries by 272.6% during the second quarter. Renaissance Technologies LLC now owns 9,786,063 shares of the company’s stock valued at $90,325,000 after buying an additional 7,159,900 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Teva Pharmaceutical Industries by 20.0% during the second quarter. Price T Rowe Associates Inc. MD now owns 9,553,328 shares of the company’s stock valued at $88,177,000 after buying an additional 1,593,139 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its stake in Teva Pharmaceutical Industries by 49.4% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 8,682,389 shares of the company’s stock valued at $59,735,000 after buying an additional 2,869,139 shares during the last quarter. Northern Trust Corp raised its stake in Teva Pharmaceutical Industries by 12.5% during the second quarter. Northern Trust Corp now owns 7,610,010 shares of the company’s stock valued at $70,239,000 after buying an additional 846,650 shares during the last quarter. Finally, Camber Capital Management LP raised its stake in Teva Pharmaceutical Industries by 85.7% during the second quarter. Camber Capital Management LP now owns 6,500,000 shares of the company’s stock valued at $59,995,000 after buying an additional 3,000,000 shares during the last quarter. Institutional investors own 57.78% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: Day Trading – Risk Worth the Reward?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.